Hospital Samaritano

samaritano.com.br

With 119 years of activity, the Samaritan is one of the country's leading centers of excellence in health. It has a Nucleus of Specialties with a focus on Cardiology, Gastroenterology, Neurology, Orthopedics, Oncology, Urology / Nephrology and Fetal / Perinatal Medicine. In addition, it has a complete and modern Service of Diagnostic and Therapeutic Medicine and Emergency area.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

HONEYWELL PARTNERSHIP AIMS TO IMPROVE PHARMA MANUFACTURING THROUGH AI

European Pharmaceutical Manufacturer Magazine | February 17, 2020

news image

The companies will combine their expertise across process automation and data analytics to aid pharmaceutical companies through a more efficient manufacturing process. Honeywell will utilise Bigfinite’s software-as-a-service (SaaS) to enhance manufacturing process operations by consolidating compliance-related manufacturing data into a single, visual interface for drug manufacturers. By combining data across laboratories, batch management, control, quality management and more, the companie...

Read More

Pharmacy Market

EYEPOINT PHARMACEUTICALS ANNOUNCES CLOSING OF $115.4 MILLION PUBLIC OFFERING

EyePoint Pharmaceuticals | November 20, 2021

news image

EyePoint Pharmaceuticals, Inc. a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced the closing of the previously announced underwritten public offering of 5,122,273 shares of its common stock, which included the exercise in full by the underwriters of their option to purchase an additional 1,095,000 shares of common stock, and pre-funded warrants to purchase up to an aggregate of 3,272,727 s...

Read More

Practice Management

ROYALTY PHARMA ACQUIRES ROYALTY INTEREST IN ORLADEYO AND BCX9930 FROM BIOCRYST PHARMACEUTICALS

Royalty Pharma | December 08, 2020

news image

Royalty Pharma, BioCryst Pharmaceuticals, Inc. what's more, Athyrium Capital Management, LP today declared exchanges adding up to $325 million in financing for BioCryst, with $250 million accessible at shutting, to help the dispatch of ORLADEYO™ (berotralstat) in genetic angioedema (HAE) and the advancement of its oral Factor D inhibitor, BCX9930. Royalty Pharma will furnish BioCryst with a forthright money installment of $125 million and will get eminences of 8.75% on d...

Read More

Business Insights

SMARTSKIN PARTNERS WITH PDA TO BRING NEW TECHNOLOGY TO ASEPTIC PROCESSING

SmartSkin Technologies and PDA | October 06, 2022

news image

SmartSkin Technologies and Parenteral Drug Association, Inc. announced a partnership to integrate SmartSkin’s data collection technologies with PDA’s aseptic processing and visual inspection training. SmartSkin is recognized by leading pharmaceutical brands as an innovator. Its technology helps the industry adapt faster and improve production quality by providing timely data from the container’s perspective inside the production process — from the washer to...

Read More
news image

HONEYWELL PARTNERSHIP AIMS TO IMPROVE PHARMA MANUFACTURING THROUGH AI

European Pharmaceutical Manufacturer Magazine | February 17, 2020

The companies will combine their expertise across process automation and data analytics to aid pharmaceutical companies through a more efficient manufacturing process. Honeywell will utilise Bigfinite’s software-as-a-service (SaaS) to enhance manufacturing process operations by consolidating compliance-related manufacturing data into a single, visual interface for drug manufacturers. By combining data across laboratories, batch management, control, quality management and more, the companie...

Read More
news image

Pharmacy Market

EYEPOINT PHARMACEUTICALS ANNOUNCES CLOSING OF $115.4 MILLION PUBLIC OFFERING

EyePoint Pharmaceuticals | November 20, 2021

EyePoint Pharmaceuticals, Inc. a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced the closing of the previously announced underwritten public offering of 5,122,273 shares of its common stock, which included the exercise in full by the underwriters of their option to purchase an additional 1,095,000 shares of common stock, and pre-funded warrants to purchase up to an aggregate of 3,272,727 s...

Read More
news image

Practice Management

ROYALTY PHARMA ACQUIRES ROYALTY INTEREST IN ORLADEYO AND BCX9930 FROM BIOCRYST PHARMACEUTICALS

Royalty Pharma | December 08, 2020

Royalty Pharma, BioCryst Pharmaceuticals, Inc. what's more, Athyrium Capital Management, LP today declared exchanges adding up to $325 million in financing for BioCryst, with $250 million accessible at shutting, to help the dispatch of ORLADEYO™ (berotralstat) in genetic angioedema (HAE) and the advancement of its oral Factor D inhibitor, BCX9930. Royalty Pharma will furnish BioCryst with a forthright money installment of $125 million and will get eminences of 8.75% on d...

Read More
news image

Business Insights

SMARTSKIN PARTNERS WITH PDA TO BRING NEW TECHNOLOGY TO ASEPTIC PROCESSING

SmartSkin Technologies and PDA | October 06, 2022

SmartSkin Technologies and Parenteral Drug Association, Inc. announced a partnership to integrate SmartSkin’s data collection technologies with PDA’s aseptic processing and visual inspection training. SmartSkin is recognized by leading pharmaceutical brands as an innovator. Its technology helps the industry adapt faster and improve production quality by providing timely data from the container’s perspective inside the production process — from the washer to...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us